Durvalumab extends survival in limited-stage small-cell lung cancer

CHICAGO — Durvalumab conferred significant survival benefits in patients with limited-stage small-cell lung cancer following standard-of-care treatment in a randomized phase 3 trial, according to findings presented at ASCO Annual Meeting.
Patients treated with durvalumab (Imfinzi, AstraZeneca) had median OS extended 22.5 months and median PFS increased more than 7 months compared with those who received placebo.
“Consolidation durvalumab will become the new standard of care for patients with [limited-stage small-cell lung cancer] who have not progressed after concurrent

CHICAGO — Durvalumab conferred significant survival benefits in patients with limited-stage small-cell lung cancer following standard-of-care treatment in a randomized phase 3 trial, according to findings presented at ASCO Annual Meeting.
Patients treated with durvalumab (Imfinzi, AstraZeneca) had median OS extended 22.5 months and median PFS increased more than 7 months compared with those who received placebo.
“Consolidation durvalumab will become the new standard of care for patients with [limited-stage small-cell lung cancer] who have not progressed after concurrent